{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:44:07Z","timestamp":1776401047429,"version":"3.51.2"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In this noncommercial, nonrandomized, open\u2010label therapeutic program POLAC project, we aimed to analyze the efficacy and safety of the pangenotypic regimen glecaprevir\/pibrentasvir (GLE\/PIB) in children aged 3\u201317 years with chronic hepatitis C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients for 8\u2010week therapy with GLE\/PIB were divided into two age groups. Patients above 12 years of age received tablets containing a fixed dose of 300\/120\u2009mg GLE\/PIB, and patients below 12 years weighing 12\u201345\u2009kg were treated with granule formula adjusted to patients' weight. The primary endpoint of the study was treatment efficacy, defined as sustained virologic response at 12 weeks posttreatment (SVR12, undetectable hepatitis C virus (HCV) RNA using a real\u2010time polymerase chain reaction).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 63 patients, 21 received tablets, and 42 received the granules formula. Median age of the patients was 8 years (interquartile range, IQR 6\u201312). There were 37 (59%) males. Fifty\u2010nine children (94%) were infected vertically. Most patients (43, 68%) had genotype 1 HCV. Four patients presented with significant fibrosis (F2\u2010F3 METAVIR) at baseline, but there were no cases of cirrhosis. Sixty\u2010two patients (98%) achieved SVR12. One patient was lost to follow\u2010up before SVR12 evaluation; however, at the end of therapy, his HCV RNA levels were undetectable. Thirty\u2010two patients (51%) had adverse events (AEs). There were 49 AEs possibly related to the treatment, all mild. The most frequent AEs included abdominal pain (14%), fatigue (11%), and pruritus (11%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study confirms that 8 weeks of therapy with GLE\/PIB in children with chronic hepatitis C is highly effective and safe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70241","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:03:40Z","timestamp":1761127420000},"page":"137-145","source":"Crossref","is-referenced-by-count":0,"title":["Glecaprevir\/pibrentasvir in patients aged 3\u201317 years with chronic hepatitis C: Real\u2010life data from the POLAC project"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-2329","authenticated-orcid":false,"given":"Anna","family":"Dobrzeniecka","sequence":"first","affiliation":[{"name":"Department of Children\u2032s Infectious Diseases Medical University of Warsaw Warsaw Poland"},{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Talarek","sequence":"additional","affiliation":[{"name":"Department of Children\u2032s Infectious Diseases Medical University of Warsaw Warsaw Poland"},{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Aniszewska","sequence":"additional","affiliation":[{"name":"Department of Children\u2032s Infectious Diseases Medical University of Warsaw Warsaw Poland"},{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Troszczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Children\u2032s Infectious Diseases Medical University of Warsaw Warsaw Poland"},{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pokorska\u2010\u015apiewak","sequence":"additional","affiliation":[{"name":"Department of Children\u2032s Infectious Diseases Medical University of Warsaw Warsaw Poland"},{"name":"Department of Pediatric Infectious Diseases Regional Hospital of Infectious Diseases in Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":". Guidelines for the Care and Treatment of Persons Diagnosed With Chronic Hepatitis C Virus Infection","author":"World Health Organization","year":"2018"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30046-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100227"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1070668"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.082"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02633.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22094"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15827"},{"key":"e_1_2_8_11_1","unstructured":"EuropeanMedicines Agency.Summary of Product Characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/overview\/maviret-epar-medicine-overview_en.pdf"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30840"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31841"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16180"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01968-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04859.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318185998f"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12830"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15744"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.12816\/0028740"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20659"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16037"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.12.011"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216949"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13081518"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2024.146131"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001968"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00028-8"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13020180"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:51:24Z","timestamp":1776397884000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/jpn3.70241"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70241","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}